english.prescrire.org > Prescrire International > N°158 - March 2015

n°158

March 2015

Issue Contents
Editorial

Free  Conflicts of interest: industry versus healthcare professionals

p.60
A drug company tried to exploit the conflicts of interest concept

New Products


Teriflunomide (Aubagio°)

p.61-64
Multiple sclerosis: just a metabolite of leflunomide

Natalizumab (Tysabri°) and multiple sclerosis

p.65-67
With longer follow-up: even more toxic than suspected

Oral teicoplanin (Targocid°) and intestinal Clostridium difficile infection

p.67
Just another option

Levonorgestrel (Jaydess°) intrauterine device 6 micrograms per day

p.68
No proven advantages

INN common stem: -fentanil

p.68

Alemtuzumab (Lemtrada°) and multiple sclerosis

p.69
Biased evaluation, evidence of serious risks

Adverse Effects


Gliptins: bullous pemphigoid

p.70
Mostly in elderly men

Metronidazole: psychotic disorders added to French SPCs and patient information leaflets

p.71
Beware of large cumulative doses

Metronidazole: encephalopathy

p.71
Especially during long-term treatment

Reviews


Mammographic breast cancer screening - Part I

p.72-73
Randomised trials: uncertain, at best modest, reduction in deaths from breast cancer

Outlook


Free  2014 Prescrire Drug Awards

p.74-75

Free  The Prescrire Awards 2014

p.74-77

Free  2014 Prescrire Packaging Awards

p.76-77

Free  2014 Prescrire Information Awards

p.77

Free  Towards better patient care: drugs to avoid in 2015

p.78-79
71 drugs more harmful than beneficial

"Biosimilars": towards fewer obstacles to their use

p.80-83
Major implications for the efficient management of healthcare expenditure

The European biosimilars market remains underdeveloped

p.82

Masthead


Free  Masthead

p.58

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe